Medical Condition News

RSS

SCCA's infection control program leads to suppression of potential H1N1 pandemic

Despite a 100-fold increase in H1N1 influenza cases in the Seattle area during spring 2009, an aggressive infection control program to protect immunocompromised cancer patients and thorough screening measures resulted in no corresponding increase in H1N1 cases among the total patient population at the Seattle Cancer Care Alliance, according to a new study by researchers and physicians at Fred Hutchinson Cancer Research Center and the SCCA.

19 Dec 2009

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

Neuralstem, Inc. today announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells has been approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA.

19 Dec 2009

Understanding the differences between skull bone and bones in limbs could prevent osteoporosis

Scientists at Queen Mary, University of London have uncovered fundamental differences between the bone which makes up the skull and the bones in our limbs, which they believe could hold the key to tackling bone weakness and fractures.

19 Dec 2009

UCSF/SFGH project to improve health outcomes among diabetes patients honored

A UCSF/San Francisco General Hospital project that used a novel communication tool to improve health outcomes among diabetes patients was honored recently with a quality leadership award from the California Health Care Safety Net Institute.

18 Dec 2009

McNeil Consumer Healthcare announces recall of TYLENOL in bottles with red EZ-OPEN CAP

In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is expanding its voluntary recall to include all available product lots of TYLENOL® Arthritis Pain Caplet 100 count bottles, with the distinctive red EZ-OPEN CAP (Full list of lot numbers provided below).

18 Dec 2009

Autism Speaks calls on federal government to address the growing national autism public health crisis

In the wake of today's new report from the U.S. Centers for Disease Control (CDC) stating that autism now affects 1 in every 110 American children, Autism Speaks, the nation's largest autism science and advocacy organization, called on the federal government to immediately step up its efforts - and dramatically increase funding - to address the growing national autism public health crisis.

18 Dec 2009

Taro Pharmaceutical Industries initiates its T2007 non-sedating barbiturate compound Phase I clinical trials

Taro Pharmaceutical Industries Ltd. announced that it has begun Phase I clinical trials in Canada with T2007, the second in the Company’s class of proprietary non-sedating barbiturate compounds to be approved for studies in humans.

18 Dec 2009

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

UVA acquires Extend to broaden the potential for Gamma Knife Perfexion

Patients with overly large benign skull base tumors, lesions too close to critical anatomy and those with multiple brain metastases are among those who will benefit first from a new "frameless" device for use with Leksell Gamma Knife Perfexion systems.

From Elekta 18 Dec 2009

Medtronic launches its SOVEREIGN Spinal System in the U.S.

Medtronic, Inc. today announced the U.S. launch of the SOVEREIGN™ Spinal System.

18 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

New Thermal-Aid products reduce pain and swelling in arthritis patients

Pacific Shore Holdings, Inc., manufacturers of Burner Balm and Energy-X lip balms, today announced the launch of their new Thermal-Aid product line. These 100% natural therapeutic heating/cooling treatment packs are specifically designed to reduce swelling and relieve pain and have been developed in a variety of applications

18 Dec 2009

New stem cell based technology may eliminate brain cancer

Using a novel stem cell based technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical team may eliminate a glioma -- brain cancer -- of a 36 year old Norwegian patient in a hospital in Beijing.

18 Dec 2009

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.

18 Dec 2009

Triage NGAL bedside blood test helps identify AKI risk: New study

According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.

18 Dec 2009

SAIC receives multiple-award contract to support BUMED throughout the U.S.

Science Applications International Corporation (SAIC) today announced it has been awarded a prime contract by the U.S. Army Research, Development and Engineering Command Acquisition Center - Natick Contracting Division to support the U.S. Navy's Chief Bureau of Medicine and Surgery (BUMED) for Medical Research and Development, and their subordinate research and development commands.

18 Dec 2009

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom.

18 Dec 2009

Study provides new definition on dyslexia

Contrary to popular belief, some very smart, accomplished people cannot read well. This unexpected difficulty in reading in relation to intelligence, education and professional status is called dyslexia, and researchers at Yale School of Medicine and University of California Davis, have presented new data that explain how otherwise bright and intelligent people struggle to read.

18 Dec 2009

Medical Condition News

SCCA's infection control program leads to suppression of potential H1N1 pandemic

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

Understanding the differences between skull bone and bones in limbs could prevent osteoporosis

UCSF/SFGH project to improve health outcomes among diabetes patients honored

McNeil Consumer Healthcare announces recall of TYLENOL in bottles with red EZ-OPEN CAP

Autism Speaks calls on federal government to address the growing national autism public health crisis

Taro Pharmaceutical Industries initiates its T2007 non-sedating barbiturate compound Phase I clinical trials

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

UVA acquires Extend to broaden the potential for Gamma Knife Perfexion

Medtronic launches its SOVEREIGN Spinal System in the U.S.

GSK receives European CHMP positive opinion for Revolade

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

New Thermal-Aid products reduce pain and swelling in arthritis patients

New stem cell based technology may eliminate brain cancer

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Triage NGAL bedside blood test helps identify AKI risk: New study

SAIC receives multiple-award contract to support BUMED throughout the U.S.

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Study provides new definition on dyslexia

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News